Skip to main content

AIM ImmunoTech宣布第1期鼻内安普利近临床研究的首批健康受试者已用药

Written by Customer Service on . Posted in Public Companies.

美国佛罗里达州奥卡拉, March 08, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc.（纽交所代码：AIM）今天宣布已给第1期临床研究的首批健康受试者用药，以研究AIM的药物安普利近（Ampligen）作为一种潜在鼻内疗法的安全性。AIM的目标是开发安普利近，将其作为一种新冠病毒和其他呼吸道病毒性疾病的鼻内预防或早期治疗药物。
位于荷兰莱顿的独立机构人类药物研究中心（CHDR）正在进行一项名为“I期、随机、双盲、安慰剂对照研究，以评估对健康受试者鼻内安普利近（Poly I：Poly C12U）反复给药的安全性和活性”的临床研究。目前，此项研究计划为四个安普利近治疗组分别招募八名健康受试者以及招募八名安慰剂受试者，总共为40名健康受试者。该试验旨在评估鼻内安普利近重复给药的安全性、耐受性和生物学活性。受试者将每隔一天接受鼻内给药，为期13天，每人共7剂。AIM将为该临床研究提供资金。犹他州立大学抗病毒研究所先前的体外建模表明，安普利近能够在临床可实现的鼻内安普利近剂量水平下将SARS-CoV-2传染性病毒生成量降低90％。AIM首席执行官Thomas K. Equels表示：“我们非常感谢CHDR整个团队的巨大努力，帮助我们启动对安普利近作为潜在鼻内治疗药物的第1期研究。我们的目标是加快开发安普利近作为新冠病毒潜预防或治疗方面的进程。先前的体外建模结果极具前景，使用安普利近鼻内给药疗法来预防新冠病毒感染和传播的潜力让我们倍受鼓舞。随着这一重要试验的进展，我们期待提供更多的最新信息。”关于AIM ImmunoTech Inc.AIM ImmunoTech Inc.是一家免疫药物公司，致力于研究和开发治疗多种类型癌症、免疫疾病和病毒性疾病（包括由SARS-CoV-2病毒引起的新冠肺炎）的方法。警示声明本新闻稿载有1995年《私人证券诉讼改革法案》（“PSLRA”）所定义的“前瞻性声明”。诸如“可能”、“将会”、“预期”、“计划”、“预计”等词语和类似表达（以及其他提及未来事件或情况的词语或表达）旨在标识前瞻性声明。这些前瞻性声明中有许多涉及多项风险和不确定性。其中，公司主张对上述声明给予PSLRA中包含的前瞻性声明安全港保护。公司无法确保CHDR研究能够成功或产生有利数据，并且该试验受到许多因素影响，包括无法获得监管批准、缺乏研究药物，或申办其他试验的机构中优先事项发生变化。要确定安普利近在新冠病毒鼻内疗法中是否有效，还需要进行大量其他测试和试验，且无法保证事实将会如此。鉴于新冠肺炎紧急医疗情况，临床试验招募和报告可能会出现延误。我们不承诺对该等前瞻性陈述进行更新以反映本协议日期之后发生的事件或情况。联系方式：Crescendo Communications, LLC
电话：212-671-1021
电子邮箱：aim@crescendo-ir.comAIM ImmunoTech Inc
电话：800-789-4042
电子邮箱：IR@aimimmuno.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.